🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chunjuan Wang presents first-time data from the GOLDEN BRIDGE II study, reporting fewer new vascular events at one year and "significant improvements" in stroke care quality in hospitals using an AI-based clinical decision support system #ESOC2025 European Stroke Org

A new RCT presented at #ESOC2025 shows that adding non-invasive EECP therapy to standard care may improve brain blood flow & cut stroke recurrence risk in patients with severe ICAS—from 26.2% to 6.5%! Promising step in stroke prevention. #Stroke #Neurology #EECP

An mHealth approach has been linked to better post-stroke systolic BP control vs standard care at 12 months within PINGS-2, a large-scale study conducted in Ghana and presented today at #ESOC2025 by Bruce Ovbiagele European Stroke Org JAHA

Katharine Scrivener presents results from the FAST study, reporting a significant reduction in the rate of post-stroke falls in patients receiving a multicomponent, tailored intervention compared to a control group receiving 'usual care' #ESOC2025 European Stroke Org

Von Vascular has announced the publication in Clinical Neurology and Neurosurgery of a pivotal preclinical research study evaluating the performance of its Algo smart pump technology, used in ‘smart static mode’, versus a leading aspiration thrombectomy pump Brian Jankowitz neuronewsinternational.com/von-vascular-r…

.European Stroke Org president elect Urs Martin Fischer and Else C. Sandset introduce the final late-breaking trial session of #ESOC2025, which will feature new data on mobile stroke units, neuroprotective drugs, carotid stenting and more

.Vignan Yogendrakumar delivers MSU-TELEMED data at #ESOC2025, reporting significantly improved resource utilisation with mobile stroke units vs 'onboard neurologist' models, as well as comparable safety and minimal treatment delays European Stroke Org

Findings from the in-silico MAP-STROKE trial indicate an improvement in outcomes, particularly for LVO patients, with a personalised EMS destination selection algorithm for prehospital stroke triage in the USA #ESOC2025 European Stroke Org Cerebrovascular & Neurointerventional Lab

Uncertainty remains regarding antithrombotic treatments for ICH - while both antiplatelets and anticoagulants had a minimal impact on sICH recurrence in the STATICH trial, these data are "highly underpowered" and investigators say no conclusions can be drawn #ESOC2025 European Stroke Org

Stephen Ryan delivers TenCRAOS study results, which found no clinical benefits with early tenecteplase treatment in central retinal artery occlusion - leading the presenter to conclude that an effective reperfusion therapy for these patients is still lacking #ESOC2025 European Stroke Org

The neuroprotective drug candidate TTYP01 (edaravone) demonstrates improved functional outcomes and no negative safety signals vs placebo in ischaemic stroke patients, as per ERASE-Stroke data presented by Xinfu Zhou at #ESOC2025 European Stroke Org

🚨 Landmark Data Drop! At #ESOC2025, the CERES-TANDEM study - the largest real-world analysis on emergent carotid stenting during thrombectomy for tandem lesion stroke. 👥 4053 patients | 49 stroke centers ➡️ Improved outcomes, no excess bleeding risk #Stroke @micheleromoli

#ESOC2025 has wrapped up after 3 days of insightful sessions, expert speakers & meaningful connections. Thanks to all who participated! 📽️ Watch the highlights video and Save the Date for #ESOC2026 in Maastricht, the Netherlands #VoiceOfStroke Maastricht Convention Bureau

Revalesio has announced data from a RESCUE trial post-hoc analysis showing that patients treated with 1mL/kg/h of RNS60 plus EVT <12 hours from stroke onset had a larger numerical benefit than the overall group treated within 24 hours #esoc2025 European Stroke Org neuronewsinternational.com/revalesio-anno…

.aptaTargets has announced an agreement with German pharmaceutical giant Merck for the clinical development and commercialisation of ApTOLL, a TLR4 antagonist being developed to treat acute ischaemic #Stroke neuronewsinternational.com/merck-assumes-…

.Terumo Interventional Systems has announced the early commercial availability of its US FDA-approved Roadsaver #Carotid stent system, which is designed to treat carotid artery stenosis in patients with an increased risk of post-endarterectomy adverse events Terumo Neuro neuronewsinternational.com/terumo-announc…